Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Icosavax Inc (ICVX)

Icosavax Inc (ICVX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
15.31 -0.14 (-0.91%) 02/16/24 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 15.31 unch (unch) -
Quote Overview for Fri, Feb 16th, 2024
Day Low
15.28
Day High
15.44
Open 15.40
Previous Close 15.45 15.45
Volume 9,315,200 9,315,200
Avg Vol 1,485,225 1,485,225
Stochastic %K 48.15% 48.15%
Weighted Alpha +7.30 +7.30
5-Day Change -0.05 (-0.33%) -0.05 (-0.33%)
52-Week Range 4.75 - 16.10 4.75 - 16.10
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 766,878
  • Shares Outstanding, K 50,090
  • Annual Sales, $ 580 K
  • Annual Income, $ -91,760 K
  • EBIT $ -106 M
  • EBITDA $ -107 M
  • 60-Month Beta 1.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.30
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.22
  • Most Recent Earnings $-0.44 on 11/14/23
  • Next Earnings Date 04/04/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.54
  • Number of Estimates 4
  • High Estimate -0.49
  • Low Estimate -0.59
  • Prior Year -0.59
  • Growth Rate Est. (year over year) +8.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.17 +0.92%
on 01/23/24
Period Open: 15.61
15.78 -2.98%
on 01/18/24
-0.30 (-1.92%)
since 01/16/24
3-Month
9.38 +63.22%
on 11/17/23
Period Open: 9.31
16.10 -4.91%
on 12/13/23
+6.00 (+64.45%)
since 11/16/23
52-Week
4.75 +222.32%
on 04/20/23
Period Open: 8.87
16.10 -4.91%
on 12/13/23
+6.44 (+72.60%)
since 02/16/23

Most Recent Stories

More News
Oracle's Falling, but You Won't Want to Miss This Soaring Biotech Stock

Tuesday brought favorable inflation data, and bullish investors are looking for stock winners.

AZN : 69.57 (+0.03%)
ORCL : 138.49 (+0.71%)
ICVX : 15.31 (-0.91%)
Why Shares of Icosavax Jumped on Tuesday

The company announced positive trial news for its pan-virus vaccine.

ICVX : 15.31 (-0.91%)
Icosavax Announces Results from IVX-411 Drug Product Investigation and Outlines Additional Corporate Milestones

- Antigen component of IVX-411 found to be unstable; issue specific to molecule, with no evidence of read-through to other Icosavax programs - - Now...

ICVX : 15.31 (-0.91%)
Icosavax to Participate in the William Blair Biotech Focus Conference

SEATTLE, July 06, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP)...

ICVX : 15.31 (-0.91%)
Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV

- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older...

ICVX : 15.31 (-0.91%)
Icosavax to Participate in the Jefferies Healthcare Conference

SEATTLE, June 01, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle...

ICVX : 15.31 (-0.91%)
Why Icosavax Stock Is Soaring Today

The company's Q4 update made investors feel a little better after receiving disappointing news last week.

ICVX : 15.31 (-0.91%)
Icosavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

- Completed dosing in older adults portion of Phase 1/1b clinical trial for IVX-121, a VLP vaccine candidate displaying the prefusion stabilized...

ICVX : 15.31 (-0.91%)
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2

- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on...

ICVX : 15.31 (-0.91%)
Icosavax to Participate in the Cowen 42nd Annual Health Care Conference

SEATTLE, March 02, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle...

ICVX : 15.31 (-0.91%)
Icosavax Provides Corporate Update and Anticipated Milestones for 2022

SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP)...

ICVX : 15.31 (-0.91%)
Icosavax Appoints Dr. John Shiver to Board of Directors

- Dr. Shiver has contributed to the licensure of 14 pharmaceutical addressing global infectious diseases -...

ICVX : 15.31 (-0.91%)
Icosavax Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- Initiated a Phase 1/1b clinical trial for IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory...

ICVX : 15.31 (-0.91%)
Icosavax to Participate in Upcoming Investor Conferences

SEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP)...

ICVX : 15.31 (-0.91%)
Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update

- Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain -

ICVX : 15.31 (-0.91%)
Icosavax Appoints Elizabeth Bekiroğlu to General Counsel

SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against...

ICVX : 15.31 (-0.91%)
Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus

- Phase 1/1b clinical trial will assess the safety and immunogenicity of IVX-121 in healthy adults, including older adults -

ICVX : 15.31 (-0.91%)
Adams Street Partners Growth Equity Strategy Participates in Three High-Profile Public Offerings In Seven Days

Adams Street Partners, a private markets investment firm with $45 billion in assets under management, announced today that within a 7-day period last week three companies within its Growth Equity portfolio...

HOOD : 49.45 (+2.70%)
ICVX : 15.31 (-0.91%)
BASE : 17.07 (+0.18%)
Icosavax Mourns Sudden Passing of Tadataka Yamada, M.D. Chairman of the Company’s Board of Directors

SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against...

ICVX : 15.31 (-0.91%)
Icosavax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SEATTLE, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against...

ICVX : 15.31 (-0.91%)

Business Summary

Icosavax Inc. is a biopharmaceutical company which focuses on life-threatening respiratory diseases. The company's virus-like particle platform technology involved in developing vaccines against infectious diseases. Icosavax Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 15.57
2nd Resistance Point 15.50
1st Resistance Point 15.41
Last Price 15.31
1st Support Level 15.25
2nd Support Level 15.18
3rd Support Level 15.09

See More

52-Week High 16.10
Last Price 15.31
Fibonacci 61.8% 11.76
Fibonacci 50% 10.43
Fibonacci 38.2% 9.09
52-Week Low 4.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.